Gilead Sciences, Inc. $GILD Stock Position Decreased by Capital Research Global Investors

Capital Research Global Investors decreased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 30,014,046 shares of the biopharmaceutical company’s stock after selling 1,083,633 shares during the period. Capital Research Global Investors owned 2.42% of Gilead Sciences worth $3,331,573,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. Corundum Trust Company INC acquired a new stake in shares of Gilead Sciences in the 3rd quarter worth about $26,000. Howard Hughes Medical Institute bought a new stake in Gilead Sciences during the 2nd quarter valued at $30,000. MTM Investment Management LLC raised its stake in shares of Gilead Sciences by 176.0% during the third quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 176 shares in the last quarter. Kilter Group LLC bought a new position in Gilead Sciences in the 2nd quarter valued at about $33,000. Finally, Millstone Evans Group LLC increased its stake in Gilead Sciences by 58.7% during the 3rd quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 118 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $146.63 on Tuesday. Gilead Sciences, Inc. has a 12-month low of $93.37 and a 12-month high of $157.29. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98. The company has a market cap of $182.03 billion, a P/E ratio of 21.66, a price-to-earnings-growth ratio of 1.89 and a beta of 0.36. The company’s fifty day moving average is $138.73 and its two-hundred day moving average is $126.06.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.83 by $0.03. The company had revenue of $7.93 billion for the quarter, compared to analysts’ expectations of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The business’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Equities analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be issued a dividend of $0.82 per share. The ex-dividend date is Friday, March 13th. This represents a $3.28 annualized dividend and a dividend yield of 2.2%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s dividend payout ratio is presently 46.68%.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on GILD shares. BMO Capital Markets boosted their target price on Gilead Sciences from $135.00 to $150.00 and gave the stock an “outperform” rating in a report on Monday, January 26th. UBS Group lifted their price target on Gilead Sciences from $145.00 to $155.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Argus upped their price objective on Gilead Sciences from $135.00 to $165.00 and gave the company a “buy” rating in a report on Thursday, February 19th. Citigroup reiterated a “buy” rating on shares of Gilead Sciences in a research report on Friday. Finally, Royal Bank Of Canada increased their target price on shares of Gilead Sciences from $103.00 to $118.00 and gave the company a “sector perform” rating in a research note on Wednesday, February 11th. Twenty-three analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $156.72.

Insider Activity at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $154.44, for a total transaction of $4,324,320.00. Following the completion of the sale, the insider directly owned 120,288 shares in the company, valued at $18,577,278.72. The trade was a 18.88% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Daniel Patrick O’day sold 115,640 shares of the business’s stock in a transaction that occurred on Friday, January 23rd. The shares were sold at an average price of $135.00, for a total value of $15,611,400.00. Following the completion of the sale, the chief executive officer directly owned 566,698 shares of the company’s stock, valued at approximately $76,504,230. The trade was a 16.95% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 309,280 shares of company stock valued at $43,935,470. 0.27% of the stock is owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.